BR112018068393A2 - inibidores de cxcr-2 para o tratamento de distúrbios de artropatia por cristais - Google Patents

inibidores de cxcr-2 para o tratamento de distúrbios de artropatia por cristais

Info

Publication number
BR112018068393A2
BR112018068393A2 BR112018068393A BR112018068393A BR112018068393A2 BR 112018068393 A2 BR112018068393 A2 BR 112018068393A2 BR 112018068393 A BR112018068393 A BR 112018068393A BR 112018068393 A BR112018068393 A BR 112018068393A BR 112018068393 A2 BR112018068393 A2 BR 112018068393A2
Authority
BR
Brazil
Prior art keywords
cxcr
inhibitors
treatment
crystal arthropathy
pyrimidin
Prior art date
Application number
BR112018068393A
Other languages
English (en)
Portuguese (pt)
Inventor
Miner Jeffrey
Nanavati Payal
Original Assignee
Ardea Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ardea Biosciences Inc filed Critical Ardea Biosciences Inc
Publication of BR112018068393A2 publication Critical patent/BR112018068393A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR112018068393A 2016-03-11 2017-03-09 inibidores de cxcr-2 para o tratamento de distúrbios de artropatia por cristais BR112018068393A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662307348P 2016-03-11 2016-03-11
PCT/US2017/021570 WO2017156270A1 (en) 2016-03-11 2017-03-09 Cxcr-2 inhibitors for treating crystal arthropathy disorders

Publications (1)

Publication Number Publication Date
BR112018068393A2 true BR112018068393A2 (pt) 2019-01-15

Family

ID=59789863

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018068393A BR112018068393A2 (pt) 2016-03-11 2017-03-09 inibidores de cxcr-2 para o tratamento de distúrbios de artropatia por cristais

Country Status (10)

Country Link
US (1) US10772886B2 (cg-RX-API-DMAC7.html)
EP (1) EP3426253A4 (cg-RX-API-DMAC7.html)
JP (2) JP6883917B2 (cg-RX-API-DMAC7.html)
CN (2) CN109152780B (cg-RX-API-DMAC7.html)
AU (1) AU2017231832B2 (cg-RX-API-DMAC7.html)
BR (1) BR112018068393A2 (cg-RX-API-DMAC7.html)
CA (1) CA3017345A1 (cg-RX-API-DMAC7.html)
CO (1) CO2018010880A2 (cg-RX-API-DMAC7.html)
MX (1) MX386771B (cg-RX-API-DMAC7.html)
WO (1) WO2017156270A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109152780B (zh) 2016-03-11 2021-10-01 阿迪亚生命科学公司 用于治疗结晶性关节病症的cxcr-2抑制剂
AU2018334152A1 (en) * 2017-09-12 2020-04-23 Ardea Biosciences, Inc. CXCR-2 inhibitors for treating disorders
CN111727184B (zh) 2018-01-11 2022-06-28 深圳嘉科生物科技有限公司 Cxcr2拮抗剂
WO2021004531A1 (zh) * 2019-07-11 2021-01-14 南京明德新药研发有限公司 一种cxcr2拮抗剂的晶型及其应用
KR102260478B1 (ko) * 2019-08-19 2021-06-02 연세대학교 산학협력단 일나트륨 요소화물 결정 용해용 조성물
EP4161499A1 (en) * 2020-06-05 2023-04-12 Aristea Therapeutics, Inc. Use of a combination of colchicine and a cxcr-2 inhibitor for the treatment or prevention of familial mediterranean fever (fmf) and flare-ups thereof
WO2022162021A1 (en) * 2021-01-27 2022-08-04 Astrazeneca Ab Verinurad compositions and methods of use

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0217431D0 (en) 2002-07-27 2002-09-04 Astrazeneca Ab Novel compounds
CN1914187B (zh) 2004-01-30 2012-01-25 先灵公司 Cxc趋化因子受体配位体的结晶多晶型物
EP2311827A1 (en) 2004-08-28 2011-04-20 AstraZeneca AB Thiopyrimidine derivative, useful as an intermediate for chemokine receptor modulators.
RU2009131454A (ru) * 2007-01-19 2011-02-27 Такеда Фармасьютикалз Норт Америка, Инк. (Us) Способы предупреждения или уменьшения числа обострений подагры с применением ингибиторов ксантиноксидоредуктазы и противовоспалительных средств
EP2203432A4 (en) 2007-09-21 2011-04-27 Glaxosmithkline Llc PROCESSING METHOD
US20090093548A1 (en) 2007-10-05 2009-04-09 Mutual Pharmaceutical Company, Inc Colchine compositions and methods
EP2252327A2 (en) 2007-12-04 2010-11-24 Schering Corporation Methods of treating copd
KR20110014141A (ko) 2008-03-20 2011-02-10 카롤러스 테라퓨틱스, 인코포레이티드 염증을 치료하는 방법
CA2730477A1 (en) 2008-07-16 2010-01-21 Astrazeneca Ab Pyrimidyl sulfonaminde derivative and its use for the treatment of chemokine mediated diseases
EP2331564A4 (en) 2008-10-06 2013-02-20 Carolus Therapeutics Inc PROCESS FOR TREATMENT OF IGNITION
US8298533B2 (en) 2008-11-07 2012-10-30 Medimmune Limited Antibodies to IL-1R1
WO2010056399A1 (en) 2008-11-17 2010-05-20 Incode Biopharmaceutics, Inc. Method and composition for modulating the immune system and various inflammatory conditions comprising complement depletors
WO2010065491A2 (en) 2008-12-01 2010-06-10 Carolus Therapeutics, Inc. Methods of treating inflammatory disorders
WO2010071865A1 (en) 2008-12-19 2010-06-24 Nuon Therapeutics, Inc. Pharmaceutical compositions and methods for treating hyperuricemia and related disorders
EP2421901B1 (en) 2009-04-24 2015-10-28 Tissue Tech, Inc. Compositions containing hc ha complex and methods of use thereof
WO2011038149A2 (en) 2009-09-23 2011-03-31 Carolus Therapeutics, Inc. Methods of treating inflammation
WO2011116245A2 (en) 2010-03-19 2011-09-22 Carolus Therapeutics, Inc. Methods of treating inflammation
EP2593448A1 (en) 2010-07-13 2013-05-22 AstraZeneca AB New cristalline forms of n-[2-[[(2,3-difluoropheny)methyl)thio]-6-{[(1r,2s)-2,3- dihydroxy-1-methylpropyl]oxy}-4-pyrimidinyl]-1-azetidinesulfonamide
AU2011293612B2 (en) * 2010-08-23 2015-11-26 Syntrix Biosystems Inc. Aminopyridine- and aminopyrimidinecarboxamides as CXCR2 modulators
KR101946664B1 (ko) * 2011-07-12 2019-02-11 아스트라제네카 아베 케모카인 수용체 조절제로서의 n-(6-((2r,3s)-3,4-디히드록시부탄-2-일옥시)-2-(4-플루오로벤질티오)피리미딘-4-일)-3-메틸아제티딘-1-술폰아미드
ES2846789T3 (es) 2012-07-11 2021-07-29 Tissuetech Inc Composiciones que contienen complejos HC-HA/PTX3 y métodos de uso de los mismos
EP3220951A1 (en) 2014-11-17 2017-09-27 MedImmune Limited Therapeutic combinations and methods for treating neoplasia
CN109152780B (zh) 2016-03-11 2021-10-01 阿迪亚生命科学公司 用于治疗结晶性关节病症的cxcr-2抑制剂
US20180221312A1 (en) 2016-03-11 2018-08-09 Ardea Biosciences, Inc. Cxcr-2 inhibitors for treating disorders
AU2018334152A1 (en) 2017-09-12 2020-04-23 Ardea Biosciences, Inc. CXCR-2 inhibitors for treating disorders

Also Published As

Publication number Publication date
JP2019507791A (ja) 2019-03-22
JP6883917B2 (ja) 2021-06-09
CN113893252A (zh) 2022-01-07
CN109152780A (zh) 2019-01-04
JP2021121600A (ja) 2021-08-26
JP7126014B2 (ja) 2022-08-25
US10772886B2 (en) 2020-09-15
US20180235964A1 (en) 2018-08-23
EP3426253A1 (en) 2019-01-16
AU2017231832A1 (en) 2018-10-04
WO2017156270A1 (en) 2017-09-14
MX2018010946A (es) 2019-05-23
AU2017231832B2 (en) 2021-11-11
CO2018010880A2 (es) 2018-10-22
CN109152780B (zh) 2021-10-01
CA3017345A1 (en) 2017-09-14
EP3426253A4 (en) 2019-11-06
MX386771B (es) 2025-03-19

Similar Documents

Publication Publication Date Title
CO2018010880A2 (es) Inhibidores de cxcr-2 para tratamiento de trastornos de artropatía por cristales
CO2020003061A2 (es) Inhibidores de cxcr-2 para tratar trastornos
CR20210592A (es) Moduladores de la vía integrada del estrés
EA201792231A1 (ru) Ингибиторы индоламин-2,3-диоксигеназы и способы их применения
EA201891203A1 (ru) Гетероциклические соединения в качестве иммуномодуляторов
EA201990187A1 (ru) Антипролиферационные средства на основе пиримидина
PH12022550359A1 (en) Nonpeptide somatostatin type 5 receptor agonists and uses thereof
BR112015022462A2 (pt) inibidores de ido
EA201790998A1 (ru) Иммуннорегуляторные агенты
MX2021007146A (es) Moduladores de la via de estres integrada.
EA201992083A1 (ru) Модуляторы соматостатина и их применения
EA201691872A1 (ru) Гетероциклические соединения для применения в лечении pi3k-гамма-опосредованных расстройств
MX2016000295A (es) Inhibidores de indoleamina 2,3-dioxigenasa (ido).
EA201690708A1 (ru) Ингибиторы erk и способы применения
BR112015032595A8 (pt) inibidores de ido
MX2016002075A (es) Inhibidores de indolamina 2,3-dioxigenasa (ido).
BR112015021999A2 (pt) inibidores de indoleamina 2,3-dioxigenase (ido)
EA201691447A1 (ru) 2-амино-3,5,5-трифтор-3,4,5,6-тетрагидропиридины в качестве ингибиторов bace1 для лечения болезни альцгеймера
NZ750174A (en) Somatostatin modulators and uses thereof
MX2021011507A (es) Compuestos farmaceuticos para el tratamiento de trastornos mediados por complemento.
JOP20210330A1 (ar) مركبات بيرازولو-بيريدين عطرية غير متجانسة مستبدلة واستخدامها كمعدِّلات لمستقبل الغلوتومات "glun2b"
EA202091559A1 (ru) Способ получения модуляторов соматостатина
MX2021015508A (es) Carbamatos de piridina y su uso como moduladores del receptor glun2b.
PE20170946A1 (es) 2-amino-6-(difluorometil)- 5,5-difluoro-6-fenil-3,4,5,6-tetrahidropiridinas como inhibidores de bace1
EA201991898A1 (ru) Двойные ингибиторы magl и faah

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI N? 10196/2001, QUE MODIFICOU A LEI N? 9279/96, A CONCESS?O DA PATENTE EST? CONDICIONADA ? ANU?NCIA PR?VIA DA ANVISA. CONSIDERANDO A APROVA??O DOS TERMOS DO PARECER N? 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL N? 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVID?NCIAS CAB?VEIS.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2631 DE 08/06/2021 POR TER SIDO INDEVIDA.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]